Eric Rowinsky M.D.
Dr Rowinsky’s professional focus has been on the clinical and registrational strategies of anticancer therapeutics. Currently, Dr Rowinsky serves as an Executive Director and President at RGenix, Inc, a life sciences company focused on discovering new cancer targets using a novel microRNA platform licensed. He is also Chief Medical Officer for Hummingbird Biosciences, which has a novel platform for the unique epitope targeting of monoclonal antibodies, and also served as the Chief Scientific Officer of Clearpath Development Co, which rapidly advanced development-stage therapeutic assets to pre-defined human proof-of-concept milestones. Prior to serving in these capacities, he was the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics (2010-2015). In 2010, Dr Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer until it was acquired in 2011. From 2005 to 2010, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly. Previous to that, Dr Rowinsky held several positions at the Cancer Therapy and Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr Rowinsky is a member of the Board of Directors of Biogen, Purple Biotech, and Fortress Biosciences, all public life sciences companies, and has served on the Board of Directors of BIND Therapeutics, a life sciences company acquired by Pfizer, and Navidea Biopharmaceuticals, Inc. He played an integral role in the development and execution of clinical development and registrational strategies resulting in the approval of a wide array of classical cytotoxics, monoclonal antibodies, and targeted therapeutics worldwide. He has authored more than 310 peer-reviewed manuscripts, and serves as an editor of several cancer journals.